{"protocolSection":{"identificationModule":{"nctId":"NCT01133223","orgStudyIdInfo":{"id":"GPPG 09-587"},"organization":{"fullName":"Hospital de Clinicas de Porto Alegre","class":"OTHER"},"briefTitle":"Safety and Efficacy of the Penumbra™ System in Acute Middle Cerebral Artery (MCA) Stroke","officialTitle":"Randomized Clinical Trial Comparing Intravenous Thrombolysis With Thrombectomy by the Penumbra™ System in Patients With Middle Cerebral Artery Stem Occlusion - Pilot Study"},"statusModule":{"statusVerifiedDate":"2015-09","overallStatus":"WITHDRAWN","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-05"},"primaryCompletionDateStruct":{"date":"2015-09","type":"ACTUAL"},"completionDateStruct":{"date":"2015-09","type":"ESTIMATED"},"studyFirstSubmitDate":"2010-05-26","studyFirstSubmitQcDate":"2010-05-27","studyFirstPostDateStruct":{"date":"2010-05-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-09-02","lastUpdatePostDateStruct":{"date":"2015-09-03","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Lucas Scotta Cabral","investigatorTitle":"Lucas Scotta Cabral","investigatorAffiliation":"Hospital de Clinicas de Porto Alegre"},"leadSponsor":{"name":"Hospital de Clinicas de Porto Alegre","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"Stroke prognosis is intimately related to reperfusion. Reperfusion in acute setting can be achieved with different strategies - varying from intravenous rtPA from mechanical thrombectomy. Recently, interventional approaches have been gaining attention and playing an increasing role in stroke care. However, no solid scientifical data is available to date. The investigators want do conduct a pilot trial to test if the use of the Penumbra™ System can improve clinical outcomes in a specific stroke setting."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Stroke, mecanical thrombectomy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Thrombectomy","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Penumbra™ System"]},{"label":"Usual Care","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Recombinant tissue plasminogen activator"]}],"interventions":[{"type":"DEVICE","name":"Penumbra™ System","description":"Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)","armGroupLabels":["Thrombectomy"]},{"type":"DRUG","name":"Recombinant tissue plasminogen activator","description":"Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)","armGroupLabels":["Usual Care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Functional independence (modified Rankin Scale 0-2)","timeFrame":"3 months"}],"secondaryOutcomes":[{"measure":"Minimal or no disability (modified Rankin Scale 0-1)","timeFrame":"3 months"},{"measure":"Overall mortality","timeFrame":"7 days and 3 months"},{"measure":"Symptomatic cerebral bleeding rate","timeFrame":"48 hours, 7 days and 3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient enrolled in acute ischemic stroke protocol\n* Up to 3,5h from symptoms onset\n* Clinical findings compatible with middle cerebral artery syndrome\n* Angiotomographic evidence of proximal middle cerebral artery occlusion\n\nExclusion Criteria:\n\n* NIHSS \\< 10\n* Overt contraindication to thrombolysis or angiopgraphy\n* Disagreement with informed consent term or refusal to participate","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sheila Cristina Ouriques Martins, MD, PhD","affiliation":"Hospital de Clinicas de Porto Alegre","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hospital de Clinicas de Porto Alegre","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"90035-903","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}}]},"referencesModule":{"references":[{"pmid":"18815396","type":"BACKGROUND","citation":"Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656."},{"pmid":"11062274","type":"BACKGROUND","citation":"Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke. 2000 Nov;31(11):2552-7. doi: 10.1161/01.str.31.11.2552."},{"pmid":"8427107","type":"BACKGROUND","citation":"Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):3-13."},{"pmid":"18096842","type":"BACKGROUND","citation":"Mattle HP, Arnold M, Georgiadis D, Baumann C, Nedeltchev K, Benninger D, Remonda L, von Budingen C, Diana A, Pangalu A, Schroth G, Baumgartner RW. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke. 2008 Feb;39(2):379-83. doi: 10.1161/STROKEAHA.107.492348. Epub 2007 Dec 20."},{"pmid":"14707420","type":"BACKGROUND","citation":"Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, Sen S. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17(2-3):182-90. doi: 10.1159/000075789. Epub 2003 Dec 29."},{"pmid":"15625300","type":"BACKGROUND","citation":"Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, Cacayorin ED, Song JK, Grotta JC, Campbell MS 3rd. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke. 2005 Feb;36(2):292-6. doi: 10.1161/01.STR.0000152331.93770.18. Epub 2004 Dec 29."},{"pmid":"15017011","type":"BACKGROUND","citation":"Berlis A, Lutsep H, Barnwell S, Norbash A, Wechsler L, Jungreis CA, Woolfenden A, Redekop G, Hartmann M, Schumacher M. Mechanical thrombolysis in acute ischemic stroke with endovascular photoacoustic recanalization. Stroke. 2004 May;35(5):1112-6. doi: 10.1161/01.STR.0000124126.17508.d3. Epub 2004 Mar 11."},{"pmid":"14562985","type":"BACKGROUND","citation":"Schumacher HC, Meyers PM, Yavagal DR, Harel NY, Elkind MS, Mohr JP, Pile-Spellman J. Endovascular mechanical thrombectomy of an occluded superior division branch of the left MCA for acute cardioembolic stroke. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):305-8. doi: 10.1007/s00270-003-2719-5."},{"pmid":"20019113","type":"BACKGROUND","citation":"Kulcsar Z, Bonvin C, Pereira VM, Altrichter S, Yilmaz H, Lovblad KO, Sztajzel R, Rufenacht DA. Penumbra system: a novel mechanical thrombectomy device for large-vessel occlusions in acute stroke. AJNR Am J Neuroradiol. 2010 Apr;31(4):628-33. doi: 10.3174/ajnr.A1924. Epub 2009 Dec 17."},{"pmid":"18499798","type":"BACKGROUND","citation":"Bose A, Henkes H, Alfke K, Reith W, Mayer TE, Berlis A, Branca V, Sit SP; Penumbra Phase 1 Stroke Trial Investigators. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008 Aug;29(7):1409-13. doi: 10.3174/ajnr.A1110. Epub 2008 May 22."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000010958","term":"Plasminogen"},{"id":"D000010959","term":"Tissue Plasminogen Activator"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","asFound":"R-CHOP","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","asFound":"Health-related Quality of Life","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}